Long-Term Contraceptive Pill Use Linked With Brain Tumor Risk
The contraceptive pill desogestrel has been linked to a small increase in the risk of developing an intracranial meningioma brain tumor in new research – though the risk is relatively low, and only appears with long-term desogestrel use.
These tumors are usually non-cancerous, but can lead to neurological problems, and sometimes require surgery. Meningioma has previously been linked to synthetic progestogen drugs, like desogestrel, which are designed to mimic the natural hormone progesterone that is important in the menstrual cycle and pregnancy.
The researchers, led by a team from the French National Agency for Medicines and Health Products Safety, wanted to build on those earlier studies to check the risk for desogestrel.
The study estimated that among women using desogestrel continuously for more than five years, 1 in 17,331 would develop a tumor that requires surgery. Under five years, the risk is 1 in 67,300.
That's relatively small, and the way the study is structured means it doesn't show direct cause and effect. However, the study team is recommending caution with extended use of this contraceptive pill, and regular testing for any brain issues.
"Monitoring for meningioma should focus on women who have used desogestrel 75 micrograms for more than five continuous years, in whom we found a small risk of meningioma," write the researchers in their published paper.
"As with the other progestogens, risk increased with duration of use and after use of a progestogen of known associated increased risk."
The findings are based on records of 92,301 women, with an average age of 59.7 years. Each of the 8,391 women in that group who had undergone surgery for a meningioma were compared to 10 women without tumors, matched by age and location.
As well as noting the small risk increase, the researchers also observed that the association disappeared after a year without taking desogestrel. That's good news, and may help with future treatments.
"Although direct evidence is still lacking, stopping treatment when desogestrel-related meningioma is diagnosed may preclude the need for surgery as regression of meningioma can be expected in line with cessation of any other progestogen-induced meningioma," neurosurgeon Gilles Reuter from the Centre Hospitalier Universitaire de Liège in Belgium, who wasn't involved in the study, writes in an accompanying editorial.
In the same analysis the researchers also looked at levonorgestrel, another synthetic progestogen, but in this case the data showed no increased risk – even when it was used for more than five years.
That means taking levonorgestrel may be a better option for older women than some of the other contraceptive pills previously linked to meningioma risk – though as always, it's important that any decisions about drugs and treatment are made in consultation with health professionals.
"Generally speaking, I do not believe this study should raise cause for alarm but merely drive discussion by women with their doctor around what is the best contraceptive option for them," says obstetrician and gynecologist Gino Pecoraro, from the University of Queensland in Australia, who wasn't involved in the study.
The research has been published in The BMJ.
Just One Night of Poor Sleep Can Change How Your Brain Sees Food
Insulin Isn't Just Made by The Pancreas. Here's Another Location Few Know About.
Expert Reveals 5 Important Reasons to Avoid Alcohol When Injured
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
an hour ago
- Medscape
Metabolic Dysbiosis Score Predicts Mortality Risk in ICU
A fecal metabolic dysbiosis score (MDS) predicted 30-day mortality in critically ill patients and may help identify fecal metabolites as a potential treatable trait to improve survival in these patients. METHODOLOGY: Researchers prospectively collected fecal specimens from 196 critically ill patients (median age, 64 years; about half men) admitted to the medical intensive care unit (MICU) for non-COVID-19 respiratory failure or shock. They analyzed the specimens, defined microbiome compositions by shotgun metagenomic sequencing, and quantified microbiota-derived fecal metabolites by mass spectrometry. They then correlated microbiota features and metabolites with 30-day mortality. TAKEAWAY: Overall, 30-day mortality was 30.6%. There was no significant difference between survivors and nonsurvivors regarding age, sex, race, and comorbidity burden. Microbiota compositions of the first fecal sample after MICU admission did not independently associate with 30-day mortality, nor were there associations between single metabolites and 30-day mortality. However, by integrating the fecal metabolite concentrations of 13 microbiota-derived metabolites, the team developed an MDS that predicted 30-day mortality independent of known confounders. The MDS may complement existing tools to identify patients at high risk for mortality by incorporating potentially modifiable, microbiome-related, independent contributors to host resilience. IN PRACTICE: 'Fecal metabolic dysbiosis, determined by quantitation of 13 fecal metabolites, is independently associated with 30-day mortality after MICU admission in our cohort,' the study authors wrote. 'Therefore, fecal metabolic dysbiosis represents a potentially treatable trait to improve survival in heterogeneous critically ill patients,' and the MDS may serve as a biomarker to identify patients who might benefit from such treatment. SOURCE: The study was led by Alexander P. de Porto, PhD, University of Chicago, Chicago, and was published online in Science Advances . LIMITATIONS: The study had limitations. Patients were recruited at a single tertiary academic center and needed respiratory support or a vasopressor, and thus, the results might not be representative of the entire medical ICU population. Also, patients who did not produce a fecal sample or gave a sample that was not analyzable for metagenomics and metabolomics were excluded. DISCLOSURES: The study was funded by the Duchossois Family Institute. de Porto was funded by the Niels Stensen Fellowship. The Center for Research Informatics is funded by the Biological Sciences Division at the University of Chicago, with additional funding provided by the Institute for Translational Medicine and the National Institutes of Health (NIH). One co-author was funded by the NIH/National Heart, Lung, and Blood Institute. The authors declared having no competing interests.


Bloomberg
2 hours ago
- Bloomberg
Pimco and King Street's AmSurg Windfall Caps Ugly Distressed-Debt Saga
The sale of AmSurg, an ambulatory surgery company once part of KKR & Co.-backed Envision Healthcare Corp., caps an epic distressed-debt saga that will hand a windfall to investors that took ownership of the business after an ugly debt brawl. Pacific Investment Management Co., King Street Capital Management, and Partners Group are among the AmSurg owners netting nearly $4 billion from the deal to sell the company to Ascension Health, one of the biggest nonprofit health systems in the US.


Medscape
2 hours ago
- Medscape
Tiotropium Use in COPD Linked to Minimal Risk for Dementia
The initiation of tiotropium monotherapy was associated with, at most, a modest increase in dementia risk among older adults with chronic obstructive pulmonary disease (COPD) compared with long-acting beta 2-agonist combined with inhaled corticosteroid (LABA-ICS) over a long-term follow-up, although the clinical significance of this finding remains uncertain. METHODOLOGY: Researchers conducted a population-based cohort study using administrative data from Ontario, Canada, to examine whether the initiation of tiotropium monotherapy affects the risk for dementia in older adults with COPD. They included 30,960 new users of tiotropium monotherapy and compared them with 19,530 new users of LABA-ICS (mean age, 75.1 years; 46.7% women), all of whom had COPD without dementia and had started the medication from September 2004 through February 2012. The participants were followed up for a median of 7.59 years from the time of cohort entry. The study endpoint was incident dementia or censoring (death, insurance termination, or 10-year follow-up), whichever happened first. TAKEAWAY: Compared with the initiation of LABA-ICS, tiotropium monotherapy was associated with a 9% higher risk for dementia (hazard ratio [HR], 1.09; 95% CI, 1.04-1.14). However, in the secondary as-treated analysis, the initiation of tiotropium was not associated with an increased risk for dementia compared with LABA-ICS (HR, 1.11; 95% CI, 0.93-1.32). Subgroup analysis revealed an 18% higher risk for dementia with tiotropium monotherapy vs LABA-ICS in adults younger than 75 years and a 12% higher risk in men. IN PRACTICE: 'On balance, this evidence does not provide a compelling argument that patients with COPD should avoid tiotropium due to concerns about cognitive decline,' the authors of the study wrote. SOURCE: This study was led by Che-Yuan Wu, University of Toronto, Toronto, Ontario, Canada. It was published online on May 19, 2025, in JAMA Internal Medicine. LIMITATIONS: This study was potentially confounded by unmeasured factors such as smoking, dyspnea, peripheral biomarkers, spirometry measures, and other anticholinergic drugs. The assumption that the LABA-ICS comparator had no effect on the risk for dementia might not be true. The data for midlife medication dispensing and dementia biomarkers were unavailable. DISCLOSURES: This study was supported by the Heart-Brain Connection Brain-Heart Research Integrative Innovation Team Endeavor IMPACT Award from the Heart and Stroke Foundation of Canada, Brain Canada, and other sources. Few authors reported receiving financial support and grants from study funders and other sources.